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MiRNAs are short, non-coding RNA molecules that regulate gene expression post-
transcriptionally. Over the past decade, misregulated miRNA pathways have been
associated with various diseases such as cancer, neurodegenerative diseases, and
neurodevelopmental disorders. In this article, we aim to discuss the role played by
miR-128 in neuropsychiatric disorders, and highlight potential target genes from an in
silico analysis of predicted miR-128 targets. We also discuss the differences of target
gene determination based on a bioinformatics or empirical approach. Using data from
TargetScan and published reports, we narrowed the miR-128 target gene list to those
that are known to be associated with neuropsychiatric disorders, and found that these
genes can be classified into 29 gene clusters and are mostly enriched in cancer and
MAPK signaling pathways. We also highlight some recent studies on several of the
miR-128 targets which should be investigated further as potential candidate genes for
therapeutic interventions.
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INTRODUCTION
Mature microRNAs (miRNAs) are endogenous, small (approximately 22 nucleotides long), non-
coding RNA molecules which regulate their target genes post-transcriptionally by targeting the 3′
untranslated region (UTR), 5′UTR and coding regions of target messenger RNAs (mRNAs) thus
causing translational repression or mRNA degradation (Lewis et al., 2005; Bartel, 2009; Lee et al.,
2009; Schmiedel et al., 2015).
MicroRNA-128 (miR-128) is an intronic miRNA and the mature miR-128 form is encoded by
the two isoforms; miR-128-1 andmiR-128-2 (Megraw et al., 2010). The pri-miR-128-1 gene resides
within the R3H domain containing protein 1 gene (R3HDM1) and pri-miR-128-2 lies within the
cAMP-regulated phosphoprotein, 21 kDa gene (ARPP21, also known as regulator of calmodulin
signaling, RCS). This organization is conserved in human, rat and mouse genomes.
Early studies onmiR-128 pointed to its tumor suppressive activity. Loss ofMIR-128was reported
in human lung cancers – due to a deletion in chromosome 3p which included the MIR-128-2 and
ARPP21 locus (Weiss et al., 2008) and in breast cancer (Qian et al., 2012).
Apart from its anti-cancer activity, miR-128 is of particular interest to neuroscientists as it is
a brain-enriched miRNA which is highly expressed in the cortex and cerebellum, with distinct
patterns of expression in developing brains and maturing cortical neurons (Krichevsky et al.,
2003; Kim et al., 2004; Smirnova et al., 2005). Overexpression of miR-128 promotes neuronal
diﬀerentiation in P19 cells and in primary embryonic neural stem cells through the suppression
of non-sense-mediated decay (Bruno et al., 2011; Karam and Wilkinson, 2012). MiR-128-
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transduced human induced pluripotent stem cells shows similar
characteristics as mature neurons and enhances the expression of
beta-tubulin and other neuronal markers (Zare et al., 2015).
Recent studies have begun to relate MIR-128 and ARPP21
with neuropsychiatric disorders such as fear response, anxiety,
intellectual disability and in movement disorders (Lin et al., 2011;
Davis et al., 2012; Marangi et al., 2013;Tan et al., 2013). Tan et al.
(2013) observed early onset fatal epilepsy and increased neuronal
activity inmice withmiR-128 deﬁciency. In this study, dopamine-
1 receptor neurons with suppressed miR-128 expression showed
enhanced dendritic excitability and increased dendritic spine
formation. Recently, a family with a deletion of the MIR-128-
2 and ARPP21 locus (chromosome 3p22.3p22.2) was reported
to present with intellectual disability and epileptic episodes
(Marangi et al., 2013). Several family members also had two
other chromosomal abnormalities (3p24.3 deletion and 6p22.31
duplication), and suﬀered from febrile seizures during early
childhood and decreased muscle tone. However, no direct link to
ARPP21 or MIR-128 was discussed in the paper. It is interesting
to note that a deletion in the same locus can also give rise to
lung cancer, mentioned above (Weiss et al., 2008). The actual
phenotype that manifests may be subject to environmental factors
or other uncharacterised genetic factors.
Further evidence of the key role of MIR-128 in cognitive
function comes from studies where mice were trained on a fear-
conditioning paradigm, and the level of miR-128 expression was
observed to increase upon learning the associated tasks (Lin et al.,
2011). Interestingly, knockout Arpp21/Rcs mice showed anxiety-
like behavior and had decreased motivation in food-rewarded
tasks (Davis et al., 2012). However, in these papers there is no data
to directly link miR-128 to these phenotypes and it may be that
the abnormalities seen could involve other pathways, perhaps
through Arpp21/Rcs direct interaction with calmodulin.
Several lines of evidence point to miR-128 and Arpp21
being susceptible to pharmacological modulation in relation
to schizophrenia and depression. Rats administered with the
antipsychotic drug, haloperidol, exhibited an increase in the
expression ofmiR-128 in the prefrontal cortex, but no diﬀerences
were seen in human schizophrenic patients when compared
to controls (Perkins et al., 2007). MIR-128-1 overexpression
has been also reported in the dorsolateral prefrontal cortices
of schizophrenic patients (Beveridge et al., 2010) and patients
with major depression treated with selective serotonin reuptake
inhibitor antidepressant treatments, showed an upregulation
of MIR-128 in their blood (Bocchio-Chiavetto et al., 2013).
However, these studies do not conclusively show that the MIR-
128 upregulation was due to the psychiatric disorders alone, or
whether the elevation was in part due to the drug treatment.
Given that there is mounting evidence that MIR-128 is
important in neuropsychiatric/ neurological disorders, and the
recent Tan et al. (2013) report listing 1061 target genes of miR-
128, we aimed to pull together results from numerous reports to
determine what were the most likely candidate genes involved in
this pathological process. We compared the target gene dataset
from Tan et al. (2013) with datasets obtained through TargetScan
analysis and searched the literature for reported target genes, to
enable further exploration into their potential neuropsychiatric
role. Using this approach, we narrowed down the list of potential
target genes to 108. These genes can be classiﬁed into several
functional clusters and share biological pathways that are relevant
as possible therapeutic targets for neuropsychiatric disorders.
IN SILICO ANALYSIS FOR miR-128
TARGET GENES
We performed a TargetScan analysis to determine the predicted
target genes of miR-128. TargetScan (www.targetscan.org) is
an online miRNA target site prediction database which selects
possible target genes based on identifying the conserved 7-
8mer miRNA sequences on the 3′UTR of these genes that are
complementary with the miRNA seed region (Lewis et al., 2005).
This analysis identiﬁed 801 genes as potential miR-128 targets
(TargetScan release 6.2, named as Data TS, Figure 1A).
We then used data from Tan et al. (2013) where a HITS-CLIP
(high-throughput sequencing of RNA isolated by crosslinking
immunoprecipitation) approach identiﬁed 1061 genes (Dataset
T). This dataset was speciﬁc to genes which were in an
RNA-induced silencing complex (RISC) with miR-128 in adult
Camk2a-neurons. Tan et al. (2013) further deﬁned their dataset
by comparing the genes found in the RISC complex with genes
that were found to be upregulated in miR-128 knockout D1
neurons, resulting in a smaller pool of 154 genes. The majority
of the genes within this smaller dataset were enriched in the ERK
pathway and other pathways relevant to neuronal function like
ion transport, voltage-gated ion channel activity and G-protein
signaling.
Next, we compared the two datasets from TargetScan (801
genes) and Tan et al. (2013; 1061 genes) which indicated
214 genes were commonly shared (Data TS & T, Figure 1A,
Supplementary Table S1).
In addition, we performed a literature review for genes that
had been empirically identiﬁed as direct targets of miR-128.
From this, 50 genes (Dataset P) were identiﬁed (source: PubMed,
Scopus May 2015; Supplementary Table S2). Out of these 50
genes, 9 genes (Arpp21, Bmi1, Csf1, Irs1, Casc3, Mapk14, Rxra,
Snap25, and Sp1) were also shared by Dataset TS &T (Figure 1A),
meaning that these nine genes were identiﬁed by Tan et al. (2013)
TargetScan and are conﬁrmed targets ofmiR-128 (Table 1).
We noticed that some of the published miR-128 target
genes were not identiﬁed by Tan’s study, such as Bcl-2
associated X protein (Bax; Adlakha and Saini, 2011), cAMP
responsive element binding protein 1 (Creb1; Lin et al., 2011),
Doublecortin (Dcx; Evangelisti et al., 2009) (Egfr; Weiss et al.,
2008; Papagiannakopoulos et al., 2012), Neuroﬁbromin 1 (Nf1;
Paschou and Doxakis, 2012), Reelin (Reln; Evangelisti et al., 2009;
Lin et al., 2011), and Wingless-related MMTV integration site
3a (Wnt3a; Wu et al., 2014). This may indicate several issues
when determining target genes using diﬀerent approaches. In
particular, the target genes in Tan et al. (2013) were determined
using the HITS-CLIP method with adult Camk2a-neurons and
this method may have limited target gene identiﬁcation to
only genes that were expressed in those cells at that particular
time. The rationale behind using these cells is justiﬁed in
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FIGURE 1 | (A) The Venn diagram shows the number of miR-128 target genes as identified by Tan et al. (2013) TargetScan and published targets. Total number of
genes that are shared between Tan et al. (2013) and TargetScan is 214 genes; 34 genes are shared by TargetScan and our list of published miR-128 targets. (B) Top
10 functional clusters of miR-128 target genes as classified by DAVID bioinformatics tool. Using the mouse genome as the background, the threshold was set at the
following criteria: classification stringency = highest; maximum EASE score = 0.05. EASE score is a modified Fisher Exact p value which range from 0 to 1, with 0
shows perfect enrichment. (C) Biological pathways (KEGG database) shared by miR-128 target genes as annotated by the KEGG pathway database. Using the
mouse genome as background, the threshold was set at the following criteria: minimum number of genes for the corresponding pathway = 2; maximum EASE
score = 0.05.
the Tan et al. (2013) study as they were most interested in
genes that were aﬀected by the miR-128 deletion in dopamine
responsive neurons. However, this does impose a limitation to
their target gene list. TargetScan and other miRNA database
prediction software are likely to produce slightly diﬀerent lists as
these analyses are based on bioinformatics prediction software,
irrespective of the tissue expression.
Some of the genes missing from the Tan et al. (2013) dataset
included genes that are known to be expressed in the brain at
the time points used in the Tan et al. (2013) study. For example,
Dcx and Reln are known miR-128 targets and they are expressed
in adult mouse forebrains (Evangelisti et al., 2009) including the
striatum (Gates et al., 2006; Kang et al., 2011). Furthermore,
knockout Dcx and Reln mice also exhibit anxiety and epileptic
phenotypes, which are similar to the miR-128 knockout mice in
the Tan et al. (2013) study. It is unclear why these genes were not
identiﬁed. It may be that the level of expression of these particular
genes was too low to be detected or the miR-128 regulation is
speciﬁc to certain time points not included in the Tan et al. (2013)
study.
When we grouped together the dataset shared exclusively
between TS & T (205 genes) and included the dataset of
published target genes (Dataset P, 50 genes), the number
of candidate genes was 255 (Data TS and T & P). We
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TABLE 1 | Neuropsychiatric association of several miR-128 target genes
from the combined datasets TS, T, and P.
Gene Function/association with
neuropsychiatric phenotypes
Bmi1 polycomb ring finger
oncogene (Bmi1)
Promotes cell proliferation and regulates
endogenous antioxidant defense pathway
(Leung et al., 2004; Zencak et al., 2005).
Bmi1-knockout mice exhibit epileptic-like
seizures and progressive ataxia (Cao et al.,
2012).
Colony stimulating factor 1
(Csf1)
Mediates growth and differentiation of
macrophage. Target of p53 tumor suppressor
gene (Azzam et al., 2013).
Plasma Csf1 level increased in Alzheimer’s
disease patients (Laske et al., 2010).
Insulin receptor substrate 1
(Irs1)
Regulates insulin signaling (Zheng and Quirion,
2004).
Downregulated in hippocampus of an
Alzheimer’s disease model (Han et al., 2012).
Retinoid × receptor, alpha
(Rxra)
Regulates cholesterol metabolism (Gentili et al.,
2005).
The rs3132293 variant is associated with a
higher risk of Alzheimer’s disease (Kolsch et al.,
2009).
High deletion rate of RXRA in schizophrenic
patients (Lee et al., 2010).
Synaptosomal associated
protein, 25 kDa (Snap25)
Synaptosome-associated protein (Oyler et al.,
1989). Involved in docking and fusion of
synaptic vesicles (Sollner et al., 1993; Xu et al.,
2013).
Association with attention-deficit/ hyperactivity
disorder (Faraone et al., 2005).
Downregulated in hippocampi of schizophrenic
patients (Thompson et al., 2003).
Sp1 transcription factor (Sp1) A transcription factor (Dynan and Tjian, 1983).
Expressed mainly in glia (Mao et al., 2009,
2014).
Upregulates the expression of Akt-induced
vascular endothelial growth factor (Pore et al.,
2004).
Regulates the expression of Huntingtin (HTT )
gene (Wang et al., 2012).
then narrowed down the list by screening for associations
with mental and behavioral disorders (as outlined by the
International Statistical Classiﬁcation of Diseases and Related
Health Problems 10th Revision, ICD-10 version: 2010), ﬁrst
through the Genecard database (http://www.genecards.org/;
Stelzer et al., 2011, an integrated human genes compendium),
where 95 genes showed an association. The rest of the genes
were subjected to systemic review on PubMed. From both of
these two approaches, 109 genes out of the 255 genes (42.7%)
were found to have neuropsychiatric associations (Data NP;
Supplementary Figure S1 and Table S3). We then applied this
list through the Database of Annotation, Visualization, and
Integrated Discovery (DAVID) bioinformatics tool (version 6.7;
Huang et al., 2009) to determine whether any functional clusters
were enriched.
Analysis by DAVID yielded 29 functional clusters (under
highest classiﬁcation stringency), the Top 10 of which are shown
in Figure 1B (the entire list can be found in Supplementary
Table S4). These functional clusters indicated involvement in
nucleotide binding, protein kinase activity, apoptosis, neuronal
development, ion homeostasis, and maintaining cytoplasmic
membrane-bound vesicles (Figure 1B).
The KEGG annotation tool in DAVID further identiﬁed 20
shared biological pathways (Figure 1C; Supplementary Table
S5). We found several relevant neuropsychiatric pathways, such
as the MAPK signaling pathway, neurotrophin signaling and
regulation of the actin cytoskeleton which is related to neuronal
morphology. The involvement of the MAPK pathway has been
demonstrated by Tan et al. (2013), where they found that many
genes in their target dataset were associated with the ERK
pathway, and Erk2 elevation was seen in the miR-128 knockout
mice. Cancer-associated pathways accounted for a large fraction
of the genes identiﬁed (for example, in colorectal, lung, and
prostate cancers), (Figure 1C). The role ofmiR-128 and its target
genes in cancer has been discussed in an excellent review (Li et al.,
2013) and we will not discuss this aspect further.
CANDIDATE miR-128 TARGET GENES
WITH RELEVANT ASSOCIATIONS TO
NEUROPSYCHIATRIC PHENOTYPES
In this section, we aim to review some of the genes that have
been identiﬁed through the comparative analysis of the diﬀerent
datasets and are relevant to neuropsychiatric disorders. Due
to space limitations, we are unable to review all the genes
but the ones selected here are those that are involved in the
MAPK signaling pathway, neuronal development, and synaptic
plasticity.
Mapk10/JNK3
Mitogen-activated protein kinase 10 (Mapk10, or also known as
c-Jun N-terminal kinase, JNK3), a known eﬀector of Rho-GTPase
kinase, is enriched in the nervous system (Mohit et al., 1995).
Although theMapk10 gene was shown to associate with themiR-
128 binding complex in the Tan study, the expression ofMapk10
is not upregulated in miR-128-deﬁcient D1 neurons (Tan et al.,
2013). Whilst there was no change in the D1 neurons, MAPK10
is still an important gene to consider as amiR-128 target and in a
neuronal context due to its role in phosphorylating and binding
PSD-95 in dendritic spines (Kunde et al., 2013). In addition,
patients with chromosomal translocations at the MAPK10 locus
present with epileptic seizures, motor and cognitive delays
(Shoichet et al., 2006; Kunde et al., 2013) and a recent behavioral
study by Reinecke et al. (2013) reported that Mapk10 knockout
mice showed signs of anxiety as they were less active and did
not exhibit normal navigational behavior during theMorris water
maze task. The authors hypothesize the behavior could be due
to impaired neuronal plasticity as MAPK/JNKs are involved in
synaptic development (Tararuk et al., 2006).
Arpp21/Rcs
ARPP21, a cytosolic neuronal phosphoprotein, is highly
expressed in the mammalian central nervous system especially
within the basal ganglia (Walaas et al., 1983; Ouimet et al., 1989).
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Arpp21 functions as a calmodulin (CaM) signaling regulator
(and it is also known as Regulator of calmodulin signaling,
Rcs) (Rakhilin et al., 2004). CaM plays an important role at the
synapse as it regulates the release of neurotransmitters from
the presynaptic terminal (Ando et al., 2013). Phosphorylation
of serine residue 55 (Ser55) by protein kinase A (PKA) in
Arpp21 also leads to an increased binding to CaM, which
inhibits the CaM activity, and in turn aﬀects calcineurin, a CaM-
dependent phosphatase 2B, and CaM kinase I (CaMKI) activities
(Williams et al., 1989; Rakhilin et al., 2004). PKA phosphorylates
Arpp21 at the Ser55 residue and this phosphorylation can be
modulated by D1 and D2 receptor agonists whereby, there was
increased phosphorylation upon D1 receptor agonist treatment,
but decreased phosphorylation when exposed to D2 receptor
agonists (Caporaso et al., 2000). In addition, this phosphorylation
is sensitive to methamphetamine and cocaine (Caporaso et al.,
2000), which is not surprising, given its expression within the
limbic system. Taken together, data from several studies (Megraw
et al., 2010; Davis et al., 2012; Tan et al., 2013) and its role in
the CAM kinase pathway strongly indicates a potential role
for Arpp21 in regulating the development of neuropsychiatric
symptoms.
There are six out of seven genes (nine genes in total excluding
Mapk19 and Arpp21; Figure 1A) present in Dataset TS, T, and
P that have been reported to be associated with neurologically
relevant functions (Table 1). For the seventh gene, cancer
susceptibility candidate 3 (Casc3, or known as Mln51), most
reports link this gene to non-sense-mediated mRNA decay
(Chang et al., 2007) and the exon junction complex (Chazal et al.,
2013) but there are no reports so far of any association with
neurological/neuropsychiatric functions.
In addition to the candidate genes (which were shared by all
datasets) reviewed above and in Table 1, we also reviewed other
genes with highly suggestive neuropsychiatric associations, which
were identiﬁed either through the TargetScan prediction and/or
through literature reviews.
Reln
Reln is an extracellular glycoprotein secreted by Cajal-Retzius
cells during prenatal development (Del Rio et al., 1997) and has
an important role in neuronal migration (Frotscher et al., 2009).
Reln is a direct target ofmiR-128 (Evangelisti et al., 2009; Lin et al.,
2011).
RELN expression is downregulated in schizophrenia, bipolar
disorders (Guidotti et al., 2000), autism (Fatemi et al., 2005),
and Alzheimer’s disease (Herring et al., 2012). Polymorphisms
in RELN associate with the risk of developing schizophrenia
in the Han Chinese female population (Kuang et al., 2011),
but this has not been corroborated by Ovadia and Shifman
(2011). Rather, what they found was that the shorter isoform of
RELN was signiﬁcantly reduced in bipolar samples and an allelic
imbalance of RELN expression in schizophrenia samples. The
authors speculate that epigenetic factors or genetic imprinting
may be responsible for the abnormal RELN function in these
disorders.
Reln homozygous mutant mice have abnormal brain
development and an enhanced rate of seizures (Patrylo et al.,
2006; Qiu et al., 2006). In addition, Qiu et al. (2006) observed
a reduction in freezing behavior (animal stops moving due to
fear) which is associated with a defect in associative learning but
other anxiety-like behaviors were normal. Similarly, no stress-
and anxiety-like behaviors were found in Reln heterozygous
mice (Teixeira et al., 2011), but they found that mice with Reln
overexpressed were less susceptible to depressive-like behaviors
and were resistant to chronic cocaine stimulation.
An interesting study has shown that cleavage at a particular
site on the RELN protein (known as N-t), can sustain RELN
activity beyond the normal range of the wildtype protein in an
in vitro model (Koie et al., 2014), which may point to a potential
therapeutic target for certain neuropsychiatric disorders.
Dcx
DCX is a microtubule associated protein which binds to
microtubules to enable neuronal migration (Koizumi et al., 2006;
Moores et al., 2006). DCX is also involved in the dynamic
development of dendrites through regulating their length,
branching point and complexity of the dendrites (Cohen et al.,
2008). In addition, DCX regulates the distribution of neurofascin,
a cell surface adhesion molecule at the outer surface of the
cell in a microtubule-independent manner (Yap et al., 2012),
which in turn, regulate axonal outgrowth and the formation of
GABAergic synapses. DCX mutations are commonly associated
with lissencephaly, smooth brain disorder, a neuronal migration
disorder which then leads to epilepsy and mental retardation
(Jang et al., 2013).
MiR-128 inhibits the expression of Dcx by directly binding
on its 3′UTR region and inhibition of miR-128 successfully
restores the expression of Dcx (Evangelisti et al., 2009). Dcx
mutant mice exhibit a range of abnormal behaviors such as
hyperactivity, spontaneous seizures, impaired social interaction,
and decreased aggression (Nosten-Bertrand et al., 2008; Germain
et al., 2013). Disorganized hippocampal CA3 regions have been
observed (Nosten-Bertrand et al., 2008) and may account for the
various behaviors, but a recent study indicated that the typical
hippocampal-dependent behaviors such as spatial memory were
not impaired in Dcx knockout mice (Germain et al., 2013).
CONCLUSION
In this article, we sought to evaluate the potential role ofmiR-128
target genes in neuropsychiatric disorders. We noticed that out of
the 801 genes predicted to be targets of miR-128 by TargetScan,
only a small number of genes have been empirically proven to be
regulated by this miRNA. This indicates a large void of knowledge
of which genes are true targets of miR-128, and more research is
needed to construct a broader picture of the pathways regulated
bymiR-128.
Based on a systematic review and analysis of predicted and
current empirically determined targets of miR-128, we found
that miR-128 regulates many pathways within the cell, including
pathways involved in cancer or neuronal maturation. With
respect to neuropsychiatric phenotypes, we found an association
with many miR-128 target genes. As many of these have well
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characterized functions, we postulate that therapeutic targets can
be directed toward these known pathways and the central role
miR-128 plays in these pathways may indicate a potential role as
a biomarker for selected neuropsychiatric disorders.
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